Literature DB >> 9797043

Effects of troglitazone and pioglitazone on the action potentials and membrane currents of rabbit ventricular myocytes.

S Ikeda1, T Watanabe.   

Abstract

The effects of the antidiabetic thiazolidinediones troglitazone and pioglitazone on action potentials and membrane currents were studied in rabbit ventricular myocytes. Troglitazone (10 microM) reversibly reduced excitability of the myocytes and modified their action potential configuration. It significantly increased the stimulation threshold required to elicit action potentials and decreased action potential amplitude and the maximum upstroke velocity of the action potentials. The Inhibition of the maximum upstroke velocity by troglitazone was also significant at 1 microM. Voltage-clamp experiments revealed that troglitazone (10 microM) reversibly inhibited both the slow inward Ca2+ current and the steady-state K+ current. In contrast to troglitazone, pioglitazone (1-10 microM) had no significant effect on the excitability, action potential configuration, or membrane currents of myocytes. These results suggest that troglitazone, but not pioglitazone, modulates Na+, Ca2+ and K+ currents, leading to the changes in excitability and action potential configuration of ventricular myocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797043     DOI: 10.1016/s0014-2999(98)00557-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Cardiac ion channel modulation by the hypoglycaemic agent rosiglitazone.

Authors:  J C Hancox
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

2.  Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells.

Authors:  N Szentandrássy; G Harmati; L Bárándi; J Simkó; B Horváth; J Magyar; T Bányász; I Lorincz; A Szebeni; V Kecskeméti; P P Nánási
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

3.  Ca(2+)-sensitizing effect is involved in the positive inotropic effect of troglitazone.

Authors:  Y Furuse; K Ogino; M Shimoyama; N Sasaki; I Hisatome
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

4.  Effects of long-term pioglitazone treatment on peripheral and central markers of aging.

Authors:  Eric M Blalock; Jeremiah T Phelps; Tristano Pancani; James L Searcy; Katie L Anderson; John C Gant; Jelena Popovic; Margarita G Avdiushko; Don A Cohen; Kuey-Chu Chen; Nada M Porter; Olivier Thibault
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

5.  Enhanced inhibition of L-type calcium currents by troglitazone in streptozotocin-induced diabetic rat cardiac ventricular myocytes.

Authors:  Masaya Arikawa; Naohiko Takahashi; Tetsuya Kira; Masahide Hara; Tetsunori Saikawa; Toshiie Sakata
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

6.  Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs.

Authors:  L Lu; M J Reiter; Y Xu; A Chicco; C R Greyson; G G Schwartz
Journal:  Diabetologia       Date:  2008-02-05       Impact factor: 10.122

7.  Can the electrophysiological action of rosiglitazone explain its cardiac side effects?

Authors:  A Szebeni; N Szentandrássy; P Pacher; J Simkó; P P Nánási; V Kecskeméti
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

8.  Pioglitazone, a PPAR-γ Activator, Stimulates BKCa but Suppresses IK M in Hippocampal Neurons.

Authors:  Tsang-Shan Chen; Ming-Chi Lai; Te-Yu Hung; Kao-Min Lin; Chin-Wei Huang; Sheng-Nan Wu
Journal:  Front Pharmacol       Date:  2018-08-29       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.